Cargando…

Adverse events associated with human papillomavirus vaccines: a protocol for systematic review with network meta-analysis incorporating all randomised controlled trials comparing with placebo, adjuvants and other vaccines

INTRODUCTION: Adverse events following the injection (AEFIs) of human papillomavirus vaccine (HPVv) among female adolescents are still a major public health concern. METHODS: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension statement for systematic review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Jiro, Noma, Hisashi, Sakanishi, Yuta, Kawamura, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707669/ https://www.ncbi.nlm.nih.gov/pubmed/31439596 http://dx.doi.org/10.1136/bmjopen-2018-026924

Ejemplares similares

Association between administration or recommendation of the human papillomavirus vaccine and primary care physicians’ knowledge about vaccination during proactive recommendation suspension: a nationwide cross-sectional study in Japan
por: Sakanishi, Yuta, et al.
Publicado: (2023)

Factors associated between behavior of administrating or recommending mumps vaccine and primary care physicians’ knowledge about vaccination: A nationwide cross‐sectional study in Japan
por: Takeuchi, Jiro, et al.
Publicado: (2021)

Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines
por: Hussein, Waleed M., et al.
Publicado: (2016)

Polyphosphazenes as Adjuvants for Animal Vaccines and Other Medical Applications
por: Chand, Dylan J., et al.
Publicado: (2021)

High school females and those with other vaccinations most likely to complete the Human Papillomavirus vaccine
por: Kepka, Deanna, et al.
Publicado: (2015)

Japanese physicians’ attitudes and intentions regarding human papillomavirus vaccine compared with other adolescent vaccines
por: Katsuta, Tomohiro, et al.
Publicado: (2019)

Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006–2017
por: Neha, Reddy, et al.
Publicado: (2020)

Estimating rotavirus vaccine effectiveness in Japan using a screening method
por: Araki, Kaoru, et al.
Publicado: (2015)

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
por: Griffiths, Paul D, et al.
Publicado: (2011)

All vials are not the same: Potential role of vaccine quality in vaccine adverse reactions
por: Bruce Yu, Yihua, et al.
Publicado: (2021)

Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System
por: Gong, Li, et al.
Publicado: (2020)

Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
por: Vokó, Zoltán, et al.
Publicado: (2012)

Human papillomavirus vaccine
por: Singhal, Priyanka, et al.
Publicado: (2009)

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database
por: Geier, David A., et al.
Publicado: (2016)

Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis
por: Krauss, Sara Russo, et al.
Publicado: (2022)

Progress in Vaccination of Prophylactic Human Papillomavirus Vaccine
por: Zhou, Xu, et al.
Publicado: (2020)

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes
por: Kalnin, Kirill, et al.
Publicado: (2017)

Vaccines and adjuvants
por: Wilkie, Bruce
Publicado: (1993)

Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States
por: Sonawane, Kalyani, et al.
Publicado: (2021)

Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System
por: Tatang, Collins, et al.
Publicado: (2021)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines
por: Shaw, Robert H., et al.
Publicado: (2023)

Impact of malaria and helminth infections on immunogenicity of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Tanzania()()
por: Brown, Joelle, et al.
Publicado: (2014)

ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia
por: Sharpless, Kathryn E., et al.
Publicado: (2023)

Association between human papillomavirus vaccine status and other cervical cancer risk factors
por: Bowyer, Harriet L., et al.
Publicado: (2014)

Human Papillomavirus Vaccination Strategies
por: Cachafeiro, Santiago Pérez
Publicado: (2007)

Vaccination against human papillomavirus
por: Mello, Claudia Figueiredo
Publicado: (2013)

Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan
por: Ozawa, Kazuki, et al.
Publicado: (2017)

Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
por: Kim, Young-Jae, et al.
Publicado: (2010)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
por: Bullock, Timothy N. J.
Publicado: (2021)

Immunogenicity and efficacy of a plasmid DNA rabies vaccine incorporating Myd88 as a genetic adjuvant
por: Ullas, Padinjaremattathil Thankappan, et al.
Publicado: (2014)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology
por: Doshi, Peter, et al.
Publicado: (2020)

Novel Vaccine Adjuvants
por: Agrawal, Anshu, et al.
Publicado: (2013)

Adjuvants for Coronavirus Vaccines
por: Liang, Zhihui, et al.
Publicado: (2020)

Vaccines, adjuvants and autoimmunity
por: Guimarães, Luísa Eça, et al.
Publicado: (2015)

Vaccine Adjuvant Nanotechnologies
por: Barclay, T., et al.
Publicado: (2017)

Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants
por: Bonam, Srinivasa Reddy, et al.
Publicado: (2021)

Variation in Human Papillomavirus Vaccination Effectiveness in the US by Age at Vaccination
por: Egemen, Didem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k4942nt1e5anv3i67nocnfpt7a